Pharmacokinetics of acitretin.

Acta Derm Venereol Suppl (Stockh)

Laboratory for Medical Biochemistry and Clinical Analysis, University of Ghent, Belgium.

Published: September 1994

Acitretin, the metabolite of etretinate, is eliminated far more rapidly from the human body than is etretinate. It has therefore been suggested that only a short period of contraception would be required following the completion of long-term therapy. However, recent studies have demonstrated the presence of etretinate in the plasma of acitretin-treated patients. In this paper, we review the results of studies at our centre in view of the recently discovered metabolic pathways for acitretin. Re-esterification of acitretin to etretinate, however, results in a loss of the metabolic advantages of acitretin. Because of this new knowledge, the recommended contraception period after acitretin therapy has been lengthened to 2 years.

Download full-text PDF

Source

Publication Analysis

Top Keywords

acitretin
5
pharmacokinetics acitretin
4
acitretin acitretin
4
acitretin metabolite
4
etretinate
4
metabolite etretinate
4
etretinate eliminated
4
eliminated rapidly
4
rapidly human
4
human body
4

Similar Publications

Combined Abrocitinib and Acitretin Therapy for Darier's Disease: A Case Report.

Clin Cosmet Investig Dermatol

December 2024

Institute of Dermatology, Guangzhou Medical University, Guangzhou, Guangdong, 510095, People's Republic of China.

Darier's disease (DD) is a rare chronic keratinizing skin disease characterized by dyskeratosis of epidermal cells. We report a case of DD with a medical history spanning over 20 years and recurring symptoms. Pathologically confirmed DD was treated with a combination of abrocitinib and acitretin, resulting in rapid symptom resolution within 2 weeks.

View Article and Find Full Text PDF

Background: Hidradenitis suppurativa (HS), a chronic painful inflammatory skin condition, remains a persistent challenge in dermatology. Its complex pathogenesis has yet to be fully understood, complicating the identification of effective therapeutic strategies.

Objective: This study aims to investigate the latest insights on antibiotics, hormonal/metabolic interventions, and oral retinoids in the management of HS.

View Article and Find Full Text PDF

Background: Acrodermatitis continua of Hallopeau (ACH) is a rare pustular psoriasis variant predominantly affects the distal phalanges of the fingers and toes. However, data on aggravating factors and treatment outcomes is limited.

Objective: This study aims to analyze the aggravating factors and treatment outcomes of ACH in a three-tertiary-hospital in South China.

View Article and Find Full Text PDF
Article Synopsis
  • Solid organ transplant recipients (SOTRs) face a significantly higher risk of skin cancer due to long-term use of immunosuppressants, but there are no standardized screening guidelines in the U.S. for this population.
  • A scoping review analyzed 36 studies published from 2019 to 2023, focusing on skin cancer risk stratification, screening protocols, and preventive treatments for SOTRs, revealing that most studies emphasize screening and chemoprevention.
  • The SUNTRAC tool was identified as a validated model for assessing skin cancer risk, with various preventive strategies suggested, and the review calls for standardized guidelines and more research on patient education and the tool's validation in diverse groups.
View Article and Find Full Text PDF

Background: Upadacitinib, a specific JAK1 inhibitor, has minimal effect on other JAK subtypes. It influences the inflammatory process in various ways. Upadacitinib has been approved for conditions such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ulcerative colitis in various countries.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!